The Effects of Risperidone and Olanzapine on Thinking - Full Text View

Sponsors and Collaborators:	Department of Veterans Affairs Janssen, LP
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00108368

Purpose

The goal of this research is to find ways to maximize the benefits of antipsychotic medications for cognition.

Hypothesis: Risperidone and olanzapine will show greater benefits than conventional medications on assessments of social cognition, particularly affect perception and social perception.

Condition	Intervention	Phase
Schizophrenia Psychotic Disorders	Drug: Risperidone Drug: Olanzapine	Phase IV

MedlinePlus related topics: Psychotic Disorders Schizophrenia

Drug Information available for: Risperidone Olanzapine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Single Group Assignment, Bio-availability Study
Official Title:	The Cognitive Effects of Risperidone and Olanzapine

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	October 2003
Estimated Study Completion Date:	March 2006

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosed with schizophrenia disorder by a DSM IV.
Competent to sign informed consent
No history of poor response to Risperdal and Zyprexa
No organic brain disease

Exclusion Criteria:

Mental retardation or any chronic medical illness which results in the patient not being appropriate for a switch to Risperdal or Zyprexa.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00108368

Locations

United States, California
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States, 90073

Sponsors and Collaborators

Department of Veterans Affairs

Janssen, LP

More Information

Publications indexed to this study:

Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff DL, Kee KS, Marder SR, Mintz J. Cognition and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007 Oct;164(10):1585-92.

Study ID Numbers:	MHBS-057-00S
Study First Received:	April 14, 2005
Last Updated:	March 27, 2008
ClinicalTrials.gov Identifier:	NCT00108368
Health Authority:	United States: Federal Government

Keywords provided by Department of Veterans Affairs:

schizophrenia
cognition
antipsychotic medication

information processing
social cognition
Psychotic

Study placed in the following topic categories:

Schizophrenia
Dopamine
Mental Disorders
Risperidone

Olanzapine
Psychotic Disorders
Serotonin
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Gastrointestinal Agents
Psychotropic Drugs
Antiemetics
Central Nervous System Depressants
Dopamine Antagonists

Antipsychotic Agents
Serotonin Uptake Inhibitors
Pharmacologic Actions
Serotonin Antagonists
Serotonin Agents
Autonomic Agents
Therapeutic Uses
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 15, 2009